Novo Nordisk floats $9 billion bid to snatch Metsera from Pfizer

Danish pharma giant Novo Nordisk has made a bold offensive bid of up to $9 billion to acquire obesity‑drug developer Metsera, offering $56.50 per share in cash plus $21.25 per share contingent on clinical and regulatory milestones — a clear attempt to outbid rival Pfizer. Pfizer had previously proposed to acquire Metsera for up to $7.3 billion, at $47.50 per share plus up to $22.50 in milestone payments. Following Novo’s unsolicited offer, Metsera’s shares jumped about 17‑19% in pre‑market trading. The takeover contest underscores the frenzied race in the obesity‑treatment space, where Novo already holds blockbusters such as Wegovy and is stepping up efforts to bolster its pipeline. Metsera is developing a monthly‑dosed drug that could gain an edge over weekly injections, adding urgency to Novo’s bid. #SlimScan #GrowthStocks #CANSLIM